Hydrobromides
Medchemexpress LLC Eletriptan hydrobromide | 177834-92-3 | 99.8% | C22H27BrN2O2S | 25 MG
Eletriptan hydrobromide (Eletriptan HBr) is a 5-HT1B and 5-HT1D receptor agonist with antimigraine activity. It has Ki values of 0.92 nM for 5-HT1B receptors and 3.14 nM for 5-HT1D receptors.
- Dose-dependently reduces carotid blood flow in anesthetized dogs (1-1000 μg/kg; i.v.)
- Inhibits dural plasma protein extravasation in anesthetized rats (30-300 μg/kg; i.v.)
- Completely inhibits extravasation from the dura mater at 100 μg/kg
- Appears as an off-white to light brown solid
Apexbio Technology LLC Teneligliptin hydrobromide 906093-29-6 10mM (in 1mL DMSO)
Teneligliptin hydrobromide (CAS 906093-29-6) is a potent dipeptidyl peptidase-4 (DPP-4) inhibitor exhibiting competitive inhibition of human and rat plasma DPP-4 with an IC50 of approximately 1 nM DPP-4 also known as CD26 is a cell surface protease involved in immunoregulation signal transduction and apoptosis In vitro Teneligliptin hydrobromide reduces reactive oxygen species and modulates cell cycle and apoptotic gene expression in human endothelial cells exposed to high glucose In vivo it ameliorates hepatic steatosis and metabolic disturbances in murine models partly through activation of hepatic AMPK This compound supports studies of metabolic oxidative and inflammatory pathways
Medchemexpress LLC Adtn hydrobromide | 13575-86-5 | 98.0% | 10 MG
ADTN hydrobromide is the hydrobromide salt of ADTN, a long-acting dopamine receptor agonist used in research to probe dopaminergic signaling. It is supplied as a small, high-purity reagent for laboratory studies and has been reported to reduce behavioral visual threshold in DA-IPC-depleted zebrafish.
- Long-acting dopamine receptor agonist.
- Used to study dopaminergic signaling and zebrafish visual behavior.
- High purity: 98.0%.
- Supplied in a small research pack suitable for small-scale assays.
- Molecular formula C10H14BrNO2, molecular weight 260.13 g/mol.
Medchemexpress LLC Darifenacin hydrobromide | 133099-07-7 | MFCD08141803 | 99.8% | C28H31BrN2O2 | 50 MG
Darifenacin hydrobromide is a selective and orally active M3 muscarinic receptor (M3R) antagonist. It exhibits high specificity for M3R, binding >20-fold more specifically than to other muscarinic receptors. This compound is valuable for studying urinary incontinence and other symptoms associated with an overactive bladder. Additionally, it has demonstrated potential in inhibiting tumor growth in colorectal cancer cells, suggesting anti-tumor effects.
- Selective and orally active M3 muscarinic receptor antagonist
- High specificity for M3R
- Useful in studying urinary incontinence and overactive bladder
- Inhibits tumor growth in colorectal cancer cells
- Exhibits anti-tumor effects
Medchemexpress LLC CCT031374 hydrobromide | 1219184-91-4 | 98.1% | 434.33 | 10 MG
CCT031374 hydrobromide is a potent inhibitor of β-catenin/transcription factor (TCF) complex signaling. It inhibits TCF-dependent transcription of genes of the Wnt signaling pathway and exhibits antitumor activity.
- Potent inhibitor of β-catenin/TCF complex signaling
- Inhibits TCF-dependent transcription of Wnt signaling pathway genes
- Has antitumor activity
eMolecules 62595-74-8 | 3-bromopiperidine-2,6-dione | Pharmablock | MFCD11053059 | 192.012 | C5H6BrNO2 | 97.000 | BrC1CCC(=O)NC1=O | 5g | 642185378
3-bromopiperidine-2,6-dione | Pharmablock | 62595-74-8 | MFCD11053059 | 192.012 | C5H6BrNO2 | 97.000 | BrC1CCC(=O)NC1=O | 5g | 642185378
eMolecules 62595-74-8 | 3-bromopiperidine-2,6-dione | Pharmablock | MFCD11053059 | 192.012 | C5H6BrNO2 | 97.000 | BrC1CCC(=O)NC1=O | 10g | 642185379
3-bromopiperidine-2,6-dione | Pharmablock | 62595-74-8 | MFCD11053059 | 192.012 | C5H6BrNO2 | 97.000 | BrC1CCC(=O)NC1=O | 10g | 642185379
Medchemexpress LLC Anisodamine hydrobromide | 55449-49-5 | 99.5% | 386.28 g/mol | C17H24BrNO4 | 10 MG
Anisodamine hydrobromide is the hydrobromide salt of anisodamine (6-hydroxyhyoscyamine), a belladonna alkaloid with muscarinic and nicotinic receptor activity. It is supplied as a high-purity research reagent for pharmacology and biochemical studies; not for clinical use.
- High purity (approximately 99.5%).
- Molecular weight 386.28 g/mol.
- Hydrobromide salt increases water solubility for aqueous assays.
- Supplied in small milligram quantities suitable for analytical and preclinical research.
- Commonly used in muscarinic receptor pharmacology and biochemical research applications.
Medchemexpress LLC Pyrithiamine hydrobromide | 534-64-5 | 96.6% | 25 MG
Pyrithiamine hydrobromide is a thiamine metabolic inhibitor supplied as a high-purity solid for laboratory research. It is used to study thiamine-dependent biochemical pathways and nervous system disease models.
- Thiamine metabolic inhibitor for biochemical research.
- Acts as a substrate for thiamine pyrophosphokinase.
- Purity 96.6% (manufacturer reported).
- Molecular formula C14H20Br2N4O and molecular weight 420.14 g·mol⁻¹.
- CAS number 534-64-5.
- Supplied as a 25 MG solid for laboratory use; not for human consumption.
Medchemexpress LLC Dihydro-β-erythroidine hydrobromide | 29734-68-7 | MFCD00153793 | >98.0% | 356.25 g/mol | C16H22BrNO3 | 10 MG
Dihydro-β-erythroidine hydrobromide is a competitive antagonist of neuronal nicotinic acetylcholine receptors (nAChRs), with selectivity for α4β2 and α4β4 subtypes. It is used as a pharmacological tool in receptor characterization, electrophysiology, and behavioral studies to probe cholinergic signaling.
- Competitive nAChR antagonist selective for α4β2 and α4β4.
- CAS number 29734-68-7.
- Chemical formula C16H22BrNO3; molecular weight 356.25 g/mol.
- Purity >98.0% (HPLC) as reported by catalog vendors.
- Typical research pack sizes: 1 mg, 5 mg, 10 mg.
- Common applications: electrophysiology, receptor pharmacology, and behavioral assays.
Medchemexpress LLC Burixafor hydrobromide | 1191450-19-7 | 98.0% | 769.01 | 200 MG
Burixafor (TG-0054) hydrobromide is a potent CXCR4 antagonist with a pIC50 of 7.4. It inhibits the binding of CXCL12 to CXCR4, antagonizes CXCL12-induced recruitment of Gαᵢ and β-arrestin2, and blocks the downstream Gαᵢ-mediated inhibitory effect on cAMP signal transduction. It mobilizes CD34+ hematopoietic stem/progenitor cells (HSPC) from the bone marrow to the peripheral blood and can be used for research on autologous hematopoietic stem cell transplantation (ASCT).
- Potent CXCR4 antagonist (pIC50 of 7.4)
- Inhibits CXCL12 binding to CXCR4
- Antagonizes CXCL12-induced recruitment of Gαᵢ and β-arrestin2
- Blocks downstream Gαᵢ-mediated inhibitory effect on cAMP signal transduction
- Mobilizes CD34+ hematopoietic stem/progenitor cells (HSPC) from bone marrow to peripheral blood
- Potential for research on autologous hematopoietic stem cell transplantation (ASCT)
